Hope therapeutics™, inc. and nrx pharmaceuticals, inc. (nasdaq:nrxp) alert investors to sanjay gupta/cnn program on ketamine, featuring kadima neuropsychiatry institute founder dr. david feifel

"'special k': the science & stigma of ketamine" on cnn, hosted by dr. sanjay gupta david feifel md phd, founder of kadima, is a global thought leader in the interventional psychiatry field kadima neuropsychiatry institute identified as planned hope flagship clinic pending acquisition closing dr. feifel is expected to join hope as chief medical innovation officer miami , jan. 14, 2025 /prnewswire/ -- hope therapeutics™, inc., ("hope"), a medical and technology driven company, and a wholly-owned subsidiary of nrx pharmaceuticals, inc. ("nrx", and collectively with hope, the "company") (nasdaq:nrxp), today alerted investors that kadima neuropsychiatry institute's founder david feifel, md phd was featured as an expert in a program on ketamine entitled "'special k': the science & stigma of ketamine" on cnn, hosted by dr. sanjay gupta. hope previously announced that kadima is identified as the company's planned flagship clinic acquisition, upon closing of the transaction.
NRXP Ratings Summary
NRXP Quant Ranking